Table 4.
Prestratified by MGMT methylation and hTERT mutation log-rank test, Cox pairwise comparison and bootstrap validation while controlling for other clinical factors (age, gender, KPS, EOR, and bevacizumab treatment) in UCLA/Kaiser cohort
| hTERT - MGMT Status | Overall Survival | Progression-free Survival | ||||
|---|---|---|---|---|---|---|
| Median Survival Log-rank P value |
HR (95% CI) P value |
Bootstrap HR (95% CI) |
Median Survival Log-rank P value |
HR (95% CI) P value | Bootstrap HR (95% CI) |
|
| MUT-M vs MUT-U | 28.3 mo vs 15.9 mo P < .0001 |
0.32 (0.23, 0.43) P < .0001 | 0.31 (0.21, 0.42) | 15.4 mo vs 7.86 mo P < .0001 |
0.36 (0.27, 0.49) P < .0001 | 0.36 (0.24, 0.49) |
| WT-M vs WT-U | 19.1 mo vs 17.8 mo P = .4290 |
0.85 (0.48, 1.52) P = .5855 | 0.90 (0.44, 1.65) | 10.8 mo vs 6.94 mo P = .6875 |
0.88 (0.47, 1.65) P = .6931 | 0.96 (0.41, 2.06) |
| MUT-U vs WT-U | 15.9 mo vs 17.8 mo P = .0973 |
1.68 (1.13, 2.50) P = .0098 | 1.73 (1.13, 2.53) | 7.86 mo vs 6.94 mo P = .1395 |
1.57 (1.05, 2.36) P = .0287 | 1.59 (0.99, 2.37) |
| MUT-M vs WT-M | 28.3 mo vs 19.1 mo P = .0231 |
0.63 (0.37, 1.06) P = .0810 | 0.64 (0.32, 1.14) | 15.4 mo vs 10.8 mo P = .0318 |
0.65 (0.37, 1.14) P = .1324 | 0.65 (0.29, 1.17) |
MUT: hTERT mutant; WT: hTERT wildtype; M: MGMT methylated; U: MGMT unmethylated.